Institution identification

Institution ID

3331511

Institution full name and acronym

Kaiser Permanente Southern California (KPSC)

ENCePP partner

No
Institution description
No information provided.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

207221 - An observational, retrospective cohort database study to assess the safety of Boostrix (U.S. formulation), a reduced tetanus, diphtheria, acellular pertussis vaccine (Tdap), following routine immunization of pregnant women in the United States.
209570 - Long-Term Effectiveness Study of Shingrix in Adults ≥ 50 Years of Age in the US (EPI-ZOSTER-031 VE US)
213825-Non-interventional (observational) post-licensure study to assess the vaccine effectiveness and safety of recombinant zoster vaccine (RZV) in the rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) patient populations in adults 18 years of age and older (EPI-ZOSTER-044 VE US)
5ARI and Prostate Cancer Mortality Study (116059)
mRNA-1273-P901, Real-World Study of the Effectiveness of Moderna COVID-19 Vaccine
Non-interventional (observational) post-licensure study to assess the effectiveness and safety of recombinant zoster vaccine in adults aged =18 years with psoriasis or psoriatic arthritis (EPI-ZOSTER-045 VE US 216976)
Post-marketing observational surveillance study to evaluate pregnancy outcomes among women who receive Heplisav-B or Engerix-B (DV2-HBV-28)
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age